Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CMS Acquires China Rights to Seven Generic Drugs from India's Sun Pharma

publication date: Aug 19, 2019

Shenzhen's China Medical System acquired China rights to seven generic drugs from India's Sun Pharma. The seven drugs were not identified, but Sun said they have China market revenues of $1 billion annually. Two months ago, CMS in-licensed two other Sun products, a treatment for dry eye and a biologic treatment for psoriasis. Sun Pharma is one of several Indian drug companies that are now bringing their products to China, usually by forming relationships with China companies. The financial details of the agreement were not disclosed. More details....

Stock symbols: (HK: 0867) (NSE: SUNPHARMA, BSE: 524715)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.